Find My Journal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, А. Л. Акопов, Alex Martínez‐Martí, Hirotsugu Kenmotsu, Yuh‐Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark L. McCleland, Elizabeth Bennett, Barbara J. Gitlitz, Heather A. Wakelee

The Lancet, 2021

Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Presbyterian Hospital, Cornell University, NewYork–Presbyterian Hospital, New York Hospital Queens, Shanghai Pulmonary Hospital, Tongji University, Sumy State University, National University Zaporizhzhia Polytechnic, Leningrad Regional Cancer Center, First Pavlov State Medical University of St. Petersburg, Shizuoka Cancer Center, National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Azienda Ospedaliera Universitaria Pisana, Sendai Kousei Hospital, Roche (China), Stanford Cancer Institute, Stanford University

Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

1439

Citations

View on Google Scholar